New immunotherapy cocktail takes on stubborn colorectal cancer

NCT ID NCT07281716

Recruiting now Disease control Sponsor: Dan Feng Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining two immunotherapy drugs—nadunolimab and toripalimab—can help people with metastatic colorectal cancer that no longer responds to chemotherapy. The study will enroll 24 participants and first check for safety, then measure how many patients' tumors shrink. Treatment continues every three weeks for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nadunolimab and toripalimab (two immunotherapy drugs)
What this could lead to: If it works, this could offer a new treatment option for people with a hard-to-treat form of colorectal cancer that has stopped responding to chemotherapy.
What could go wrong: This is an early-phase trial with only 24 participants, so results may not apply broadly. The combination may cause serious side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MICROSATELLITE STABLE COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MICROSATELLITE STABLE COLORECTAL CARCINOMA

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.